Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin

Blood

Volumn 105, Issue 1, 2005, Pages 139-144

  Savi, Pierre ^a   Chong, Beng H ^b   Greinacher, Andreas ^b   Gruel, Yves ^b   Kelton, John G ^b   Warkentin, Theodore E ^b   Eichler, Petra ^b   Meuleman, Dick ^b   Petitou, Maurice ^b   Herault, Jean Pascal ^b   Cariou, Roger ^b   Herbert, Jean Marc ^b  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; HEPARIN DERIVATIVE;

ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROPHYLAXIS; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION;

EID: 19944429124     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-05-2010     Document Type: Article

References (35)

1. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82:439-447.
2. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem [Int Ed Engl]. 1993;32:1671-1690.
3. Herbert J-M, Petitou M, Lormeau J-C, et al. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15:1-26.
4. Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis aftertotal hip replacement. N Engl J Med. 2001;344:619-625.
5. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
6. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
7. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715-1720.
8. Turpie AGG, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359:1721-1726.
9. Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2003;163:1337-1342.
10. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation. 2000;102:2726-2731.
11. MATISSE. Fondaparinux (Arixtra) in comparison to (low-molecular-weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism - The Matisse clinical outcome studies [abstract]. Blood. 2002;100:83a.
12. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur Heart J. 2001;22:1716-1724.
13. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81:214-220.
14. Greinacher A, Alban S, Dummel S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirement for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:886-892.
15. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost. 1995;74:1384-1385.
16. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR91107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8:114-117.
17. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost. 1999;5:259-266.
18. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
19. Greinacher A, Michels I, Klefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
20. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;9:344-350.
21. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
22. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996;87:4925-4936.
23. Vitale M, Tazzari P, Ricci F, et al. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry. 2001;46:290-295.
24. Poley S, Mempel W. Laboratory diagnosis of heparin-induced thrombocytopenia: advantages of a functional flow cytometric test in comparison to the heparin-induced platelet-activation test. Eur J Haematol. 2001;66:253-262.
25. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol. 1996;95:161-167.
26. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced platelet activation test (HIPA) in comparison with a PF4/Heparin ELISA. Thromb Haemost. 1999;81:625-629.
27. 14C- serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111:700-706.
28. McCullagh P, Neider JA. Generalized Linear Models. London, United Kingdom: Ed Chapman and Hall; 1983.
29. Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262:992-1000.
30. Israels SJ, Gerrard JM, Jacques YV, et al. Platelet dense granule membranes contain both granulophysin and P-selectin (GMP-140). Blood. 1992;80:143-152.
31. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 1991;266:24302-24307.
32. Warkentin TE, Sheppard JAI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
33. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica. 2003;88:ECR32.
34. D'Amico EA, Villaca PR, Gualandro SF, Bassitt RP, Chamone DA. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:2452-2453.
35. Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Thromb Res. 2002;105:117-123.